Astrotech Corporation — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2013, compared primarily with fiscal 2012. The request metadata says “2011 Q4,” but the filing is for FY2013; it is an annual report, not a quarterly filing.
Business context
Astrotech provides satellite and payload processing, launch support, and related equipment through Astrotech Space Operations (ASO). Its Spacetech unit includes 1st Detect, developing compact mass spectrometers, and Astrogenetix, researching microgravity-based vaccines. ASO generated 99% of FY2013 consolidated revenue, leaving the company highly dependent on its core launch-services business.
Key financial results
| Metric | FY2013 | FY2012 | Change / context |
|---|---|---|---|
| Revenue | $24.0 million | $26.1 million | Down $2.1 million (about 8%); lower U.S. Government ground support equipment fabrication revenue |
| Gross profit / margin | $8.3 million / 35% | $7.3 million / 28% | Margin improved with greater satellite processing and less GSE fabrication activity |
| Operating loss | $0.6 million | $2.3 million | Improved by $1.7 million |
| Net loss attributable to Astrotech | $0.2 million | $2.7 million | Improved by $2.5 million; basic and diluted loss per share was $0.01 versus $0.15 |
| Operating cash flow | $(2.9) million | $(4.1) million | Cash use narrowed, but remained negative |
| Capital expenditures / investing cash flow | $1.8 million / $(1.8) million | $1.3 million / $(1.3) million | FY2013 spending included 1st Detect facilities |
| Cash and cash equivalents | $5.1 million | $10.2 million | Down $5.1 million during FY2013 |
| Working capital | $4.3 million | $4.8 million | Down $0.5 million |
| Term debt | $6.0 million | $6.4 million | Scheduled principal payments; secured by ASO assets |
| Backlog | $25.5 million | Not stated here | Includes contractual backlog and scheduled but uncommitted missions |
FY2013 revenue was $23.9 million from ASO and $0.1 million from Spacetech. Spacetech reported a $3.8 million net loss; management described the unit as early-stage, with limited sales and continued funding needs. About 66% of company revenue came from NASA and U.S. Government contracts or subcontracts, versus 68% in FY2012.
Liquidity, debt and outlook
Management said existing cash and expected operating proceeds, together with backlog, should fund operations and expected liquidity needs for at least the next fiscal year. This outlook is subject to customer collections, launch timing, product development spending, and other capital needs. No quantified revenue or earnings guidance is provided.
The $7.0 million term loan matures in October 2015, bears interest at prime plus 0.25% subject to a 4.0% floor, and had a $6.0 million balance at June 30, 2013. The company was out of compliance with its debt-service coverage covenant during FY2013 but received a bank waiver. It projected possible covenant noncompliance in FY2014; an October 11, 2013 amendment adjusted covenant calculations and required minimum cash balances of $2.0 million through June 30, 2014 and $0.75 million thereafter. The company expected compliance through June 30, 2014 under the amendment. The amendment is a subsequent event after the fiscal year-end.
Material changes, risks and unusual items
- Revenue declined, but gross margin improved as the business mix shifted toward satellite payload processing and away from lower-margin GSE fabrication.
- Cash fell by $5.1 million, and operating activities used $2.9 million. Accounts receivable rose to $5.3 million from $1.9 million, including unbilled amounts; 56% of receivables were attributable to the U.S. Government.
- ASO’s fixed-price contracts and launch-dependent activity expose results to cost overruns, schedule changes, and quarterly volatility. Backlog includes uncommitted missions and can be terminated by customers.
- Spacetech’s commercial success, funding, regulatory approvals, intellectual-property protection, and ability to generate meaningful sales remain uncertain.
- NASDAQ had notified the company that its share price was below the $1.00 minimum bid requirement. The grace period ran through November 11, 2013; the company said it might pursue a reverse stock split. The filing does not establish the ultimate outcome.
- Two lawsuits were disclosed: a former CFO’s contract claims seeking at least $639,808, and a shareholder derivative action alleging fiduciary-duty breaches related to corporate transactions. The company said it would vigorously defend both.
- The company fully reserved a $0.7 million note receivable from the buyer of its former Cape Canaveral facility in FY2012; no payment had been made by June 30, 2013.
- The State of Texas provided 1st Detect $1.8 million, accounted for as equity, subject to conditions and a stock-purchase right. Management said no default had occurred and considered default unlikely.
- The independent auditor issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor did not attest to internal-control effectiveness.
Most important facts for investors to verify
- Whether the company generated enough cash after year-end to maintain required bank balances and meet amended debt covenants.
- Debt maturity and refinancing options, covenant compliance, and any further lender waivers or amendments.
- Cash conversion and collection of the increased receivables, especially unbilled government-contract balances.
- Actual conversion of the $25.5 million backlog into revenue, including the proportion tied to uncommitted missions.
- Progress toward commercial sales and reduced cash needs at 1st Detect and Astrogenetix.
- Resolution and potential financial exposure from the two lawsuits, the NASDAQ bid-price deficiency, and the Texas funding conditions.